Smart science to improve lives™

Appointment of Non-Executive Director Nawal Ouzren

10 January 2022

The Board of Croda International Plc is pleased to announce the appointment of Nawal Ouzren as non-executive director.  Nawal will join the Board with effect from 1 February 2022.

Nawal has 20 years of expertise across a wide range of business roles, including clinical development, operational and strategic management roles within the pharmaceutical industry.  Nawal currently serves as CEO at Sensorion, a Euronext listed biopharmaceutical company headquartered in France. 

A chemical engineer by training, Nawal started her career at GE in operations management, manufacturing and quality and then held executive roles at Baxter International, Baxalta and Shire before joining Sensorion in 2017. 

Nawal brings with her first-hand experience in biologics and novel gene therapies and is a current serving non-executive director of Arena Pharmaceuticals, the US headquartered biopharmaceutical company. 

On joining the Croda Board, Nawal will also be appointed to the Audit, Nomination and Remuneration Committees. 

Anita Frew, Chairman of Croda International Plc, said, 
 
"I am delighted to welcome Nawal to the Croda Board. 

Nawal’s deep understanding of the biotech industry and her strong P&L, operational management and manufacturing experience will be of great benefit to Croda. Nawal brings a truly international perspective to the Board, having lived, and worked in numerous countries throughout her career.  Nawal’s appointment broadens our Board’s healthcare sector experience, cultural and geographical perspectives and management competences and ideas, and I am really pleased that our Board is now gender balanced.

Her appointment builds on the existing Life Sciences knowledge and experience we have around the Board table in support of our strategic plans to deliver our ambition in these fast-growing markets.”

There are no further matters to be disclosed under LR9.6.13R of the Listing Rules of the UK Listing Authority.